263 related articles for article (PubMed ID: 32157379)
41. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
42. Surgical Management of Metastatic Colorectal Cancer: A Single-Centre Experience on Oncological Outcomes of Pulmonary Resection vs Cytoreductive Surgery and HIPEC.
Wong EYT; Tan GHC; Ng DWJ; Koh TPT; Kumar M; Teo MCC
J Gastrointest Cancer; 2017 Dec; 48(4):353-360. PubMed ID: 27864747
[TBL] [Abstract][Full Text] [Related]
43. The Safety of Iterative Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis: A High Volume Center Prospectively Maintained Database Analysis.
Bekhor E; Carr J; Hofstedt M; Sullivan B; Solomon D; Leigh N; Bolton N; Golas B; Sarpel U; Labow D; Magge D
Ann Surg Oncol; 2020 May; 27(5):1448-1455. PubMed ID: 31873928
[TBL] [Abstract][Full Text] [Related]
44. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.
Koole SN; Kieffer JM; K Sikorska ; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham MAPC; Aalbers AG; Verwaal VJ; Van de Vijver KK; Sonke GS; van Driel WJ; Aaronson NK
Eur J Surg Oncol; 2021 Jan; 47(1):101-107. PubMed ID: 31128948
[TBL] [Abstract][Full Text] [Related]
45. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.
Cashin PH; Graf W; Nygren P; Mahteme H
Eur J Surg Oncol; 2012 Jun; 38(6):509-15. PubMed ID: 22475555
[TBL] [Abstract][Full Text] [Related]
46. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection.
Grotz TE; Overman MJ; Eng C; Raghav KP; Royal RE; Mansfield PF; Mann GN; Robinson KA; Beaty KA; Rafeeq S; Matamoros A; Taggart MW; Fournier KF
Ann Surg Oncol; 2017 Sep; 24(9):2646-2654. PubMed ID: 28695394
[TBL] [Abstract][Full Text] [Related]
47. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
Lee L; Alie-Cusson F; Dubé P; Sideris L
J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
[TBL] [Abstract][Full Text] [Related]
48. Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Munoz-Zuluaga C; Sardi A; King MC; Nieroda C; Sittig M; MacDonald R; Gushchin V
Ann Surg Oncol; 2019 Feb; 26(2):473-481. PubMed ID: 30523470
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer.
Lei Z; Wang Y; Wang J; Wang K; Tian J; Zhao Y; Chen L; Wang J; Luo J; Jia M; Tang H; He Q; Liao Q; Yang X; Guan T; Wang L; Cui S;
JAMA Netw Open; 2020 Aug; 3(8):e2013940. PubMed ID: 32840622
[TBL] [Abstract][Full Text] [Related]
50. Critical analysis of 33 patients with peritoneal carcinomatosis secondary to colorectal and appendiceal signet ring cell carcinoma.
Chua TC; Pelz JO; Kerscher A; Morris DL; Esquivel J
Ann Surg Oncol; 2009 Oct; 16(10):2765-70. PubMed ID: 19641972
[TBL] [Abstract][Full Text] [Related]
51. Hepatectomy for metachronous colorectal liver metastases following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases: a report of three cases.
Ito K; Takemura N; Inagaki F; Mihara F; Kurokawa T; Gohda Y; Kiyomatsu T; Yano H; Kokudo N
World J Surg Oncol; 2019 Jun; 17(1):99. PubMed ID: 31196097
[TBL] [Abstract][Full Text] [Related]
52. Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases of urachal cancer.
Mertens LS; Behrendt MA; Mehta AM; Stokkel L; de Jong J; Boot H; Horenblas S; van der Heijden MS; Moonen LM; Aalbers AGJ; Meinhardt W; van Rhijn BWG
Eur J Surg Oncol; 2019 Sep; 45(9):1740-1744. PubMed ID: 31003721
[TBL] [Abstract][Full Text] [Related]
53. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases.
Choudry HA; Bednar F; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2019 May; 26(5):1445-1453. PubMed ID: 30825033
[TBL] [Abstract][Full Text] [Related]
54. A population-based study on the prognostic impact of primary tumor sidedness in patients with peritoneal metastases from colon cancer.
de Boer NL; Rovers K; Burger JWA; Madsen EVE; Brandt-Kerkhof ARM; Kok NFM; de Wilt JHW; de Reuver PH; Bos A; de Hingh IHJT; Verhoef C
Cancer Med; 2020 Aug; 9(16):5851-5859. PubMed ID: 32614506
[TBL] [Abstract][Full Text] [Related]
55. External Validation of the Prognostic Nomogram (COMPASS) for Patients with Peritoneal Carcinomatosis of Colorectal Cancer.
Demey K; Wolthuis A; de Buck van Overstraeten A; Fieuws S; Vandecaveye V; Van Cutsem E; D'Hoore A
Ann Surg Oncol; 2017 Nov; 24(12):3604-3608. PubMed ID: 28895112
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
[TBL] [Abstract][Full Text] [Related]
57. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
[TBL] [Abstract][Full Text] [Related]
58. Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands.
van Oudheusden TR; Lemmens VE; Braam HJ; van Ramshorst B; Meijerink J; te Velde EA; Mehta AM; Verwaal VJ; de Hingh IH
Surgery; 2015 Jun; 157(6):1023-7. PubMed ID: 25818658
[TBL] [Abstract][Full Text] [Related]
59. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases.
Baratti D; Kusamura S; Iusco D; Gimondi S; Pietrantonio F; Milione M; Guaglio M; Bonomi S; Grassi A; Virzì S; Leo E; Deraco M
Ann Surg Oncol; 2017 Jan; 24(1):167-175. PubMed ID: 27519353
[TBL] [Abstract][Full Text] [Related]
60. Women survive longer than men undergoing cytoreductive surgery and HIPEC for appendiceal cancer.
Rozich NS; Lewis SE; Chen S; Stewart KE; Stout MB; Dooley WC; Fischer LE; Morris KT
PLoS One; 2021; 16(4):e0250726. PubMed ID: 33930051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
